Apomorphin bei der Behandlung des Morbus Parkinson

  title={Apomorphin bei der Behandlung des Morbus Parkinson},
  author={D. Dre{\ss}ler},
  journal={Der Nervenarzt},
ZusammenfassungApomorphin ist ein seit langem bekannter hochpotenter D2-, D3- und D4-Dopaminrezeptoragonist, der sich besonders durch eine zusätzliche D1-Dopaminrezeptorwirkung auszeichnet und in der Medizin vielfältige Anwendung gefunden hat. Wegen einer weitestgehenden Inaktivierung bei der Leberpassage wird Apomorphin in der Regel subkutan angewendet. Nach raschem Wirkungseintritt ist die Wirkungsdauer auf etwa eine Stunde begrenzt. Bei seiner Wirkung ist Apomorphin unabhängig von… 
4 Citations
Intermittierende Apomorphin-Injektionen als Rescue-Therapie beim fortgeschrittenen M. Parkinson
Intermittent subcutaneous apomorphine therapy should be considered in patients with advanced Parkinson’s disease who experience recurrent off periods despite optimised oral treatment, for reliable and quick reversal of these otherwise refractory periods.
Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease.
Although clozapine can be used to treat psychosis in patients with PD, managing nausea, vomiting, hiccups, and emergent psychotic symptoms in these patients remains a challenge due to a lack of evidence for currently available options.
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].
Intermittent subcutaneous apomorphine therapy should be considered in patients with advanced Parkinson's disease who experience recurrent off periods despite optimised oral treatment, based on existing study results, indications, and contraindications.
Ventricular Bigeminy after Subcutaneous Administration of Apomorphine in a Patient with Refractory Parkinson’s Disease: A Case Report
A case of ventricular bigeminy recorded in a female patient after the administration of apomorphine is reported, and it is reported that this is the first case reported in the literature of this type of treatment for Parkinson’s disease.


The apomorphine test in parkinsonian syndromes.
It is suggested that the test can predict dopa responsiveness in IPD and may be of help in confirming a doubtful diagnosis and it has potential value in differentiating IPD from PPS.
Apomorphine in the Treatment of Parkinson's Disease
  • P. Hagell, P. Odin
  • Medicine
    The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • 2001
Subcutaneous administration, either as intermittent injections or continuous infusion, is so far the best and most applied in the treatment of advanced, fluctuating Parkinson's disease and should be tried before more invasive interventions are considered.
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease
Continuous waking day dopaminergic stimulation with apomorphine reset the threshold for dyskinesias and led to a pronounced reduction in their frequency.
Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease
The accuracy of the acutelevodopa and apomorphine challenge tests is similar to, but not superior than, that of chronic levodopa therapy in the diagnosis of idiopathic Parkinson's disease.
Central Dopamine Receptors Regulate Blood Eosinophilia in the Rat
Dopaminergic agents, dopa and apomorphine, affected biphasically the blood eosinophil count in the rat: low doses of the drug elevated, while high doses lowered it. The response to a high dose of
Apomorphine test for dopaminergic responsiveness: A dose assessment study
Subcutaneous apomorphine at the dose of 50 μg/kg is a useful tool in the differential diagnosis of parkinsonian syndromes, and the final diagnosis of IPD was in good agreeement with the response to the apomorphicine test.
Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients
It is confirmed that subcutaneous apomorphine monotherapy can reset peak‐dose dyskinesia threshold in levodopa‐treated patients and further reduce off‐period disability after all available forms of oral medication, including long‐acting dopamine agonists, have been tried.
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes
The apomorphine test is a quick, safe, reliable indicator of dopaminergic responsiveness in parkinsonian syndromes and it also has some predictive value in the assessment of an untreated patient's likely response to levodopa therapy.
Sublingual apomorphine and Parkinson's disease.
The use of imipramine and other psychotropic drugs in organic emotionalism and the pathophysiology of emotional disorders associated with brain damage.
Pharmacology and neurochemistry of apomorphine.
This chapter discusses the pharmacology and neurochemistry of apomorphine, which was first employed as a powerful emetic agent and is metabolized by O-glucuronidation, O-methylation, and, probably, by N-demethylation.